[Maximum aerobic power output in overweight and obese individuals]. / Potencia aeróbica máxima en el obeso: Valores de referencia.

BACKGROUND: The evaluation of physical fitness is important to determine workloads and to assess the effectiveness of exercise interventions in obese people. AIM: To determine the maximum aerobic power output (MAPO) in overweight and obese individuals and to establish reference parameters for the Chilean population. MATERIAL AND METHODS: One hundred five men and 218 women performed a cycle ergometer test up to 85% of their maximum heart rate. MAPO was determined by linear extrapolation of the theoretical maximum heart rate. RESULTS: Among men, MAPO values were 234.9 ± 48.4 w for body mass index (BMI) values between 30 and 34.9 kg/m2, 235.1 ± 69.7 w for BMI between 35 and 39.9 kg/m2, 270.2 ± 86.5 w for BMI over 40 kg/m2. MAPO relative values were 2.27 ± 0.5, 2.16 ± 0.6 and 1.96 ± 0.8 w/kg, respectively. Among women, MAPO was 172.6 ± 36.1 w for a BMI < 30 kg/m2, 169.2 ± 39.4 w for BMI between 30 and 34.9 kg/m2, 179.5 ± 48.8 w f179.5 ± 48.8 w for BMI between 35 and 39.9 kg/m2 and 202.3 ± 57.3 w for BMI of 40 kg/m2 or over. The relative values were 2.33 ± 0.5; 2.02 ± 0.5; 1.91 ± 0.5 and 1.81 ± 0.5 w / kg (p < 0.05). CONCLUSIONS: MAPO estimation with a cycle ergometer test is well tolerated in overweight and obese individuals. MAPO decreased along with BMI increments in women. No association between BMI and MAPO in men was observed.

Potencia aeróbica máxima en el obeso: Valores de referencia / Maximum aerobic power output in overweight and obese individuals

Background: The evaluation of physical fitness is important to determine workloads and to assess the effectiveness of exercise interventions in obese people. Aim: To determine the maximum aerobic power output (MAPO) in overweight and obese individuals and to establish reference parameters for the Chilean population. Material and Methods: One hundred five men and 218 women performed a cycle ergometer test up to 85% of their maximum heart rate. MAPO was determined by linear extrapolation of the theoretical maximum heart rate. Results: Among men, MAPO values were 234.9 ± 48.4 w for body mass index (BMI) values between 30 and 34.9 kg/m2, 235.1 ± 69.7 w for BMI between 35 and 39.9 kg/m2, 270.2 ± 86.5 w for BMI over 40 kg/m2. MAPO relative values were 2.27 ± 0.5, 2.16 ± 0.6 and 1.96 ± 0.8 w/kg, respectively. Among women, MAPO was 172.6 ± 36.1 w for a BMI < 30 kg/m2, 169.2 ± 39.4 w for BMI between 30 and 34.9 kg/m2, 179.5 ± 48.8 w f179.5 ± 48.8 w for BMI between 35 and 39.9 kg/m2 and 202.3 ± 57.3 w for BMI of 40 kg/m2 or over. The relative values were 2.33 ± 0.5; 2.02 ± 0.5; 1.91 ± 0.5 and 1.81 ± 0.5 w / kg (p < 0.05). Conclusions: MAPO estimation with a cycle ergometer test is well tolerated in overweight and obese individuals. MAPO decreased along with BMI increments in women. No association between BMI and MAPO in men was observed.

Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru.

We evaluated the efficacy of three primaquine (PQ) regimes to prevent relapses with Plasmodium vivax through an open-label randomized trial in Loreto, Peru. Vivax monoinfections were treated with chloroquine for 3 days and PQ in three different regimes: 0.5 mg/kg per day for 5 days (150 mg total), 0.5 mg/kg per day for 7 days (210 mg total), or 0.25 mg/kg per day for 14 days (210 mg total). Biweekly fever assessments and bimonthly thick smears were taken for 210 days. Recurrences after 35 days were considered relapses. One hundred eighty cases were enrolled in each group; 90% of cases completed follow-up. There were no group-related differences in age, sex, or parasitemia. Relapse rates were similar in the 7- and 14-day regimes (16/156 = 10.3% and 22/162 = 13.6%, P = 0.361) and higher in the 5-day group (48/169 = 28.4%, P < 0.001 and P = 0.001, respectively). The 7-day PQ regimen used in Peru is as efficacious as the recommended 14-day regimen and superior to 5 treatment days.